摘要
目的研究化瘀散结方对晚期非小细胞肺癌患者癌胚抗原(CEA)、细胞角蛋白19片段(CYFRA21-1)、miR及基质金属蛋白酶(MMP)表达的影响。方法以2015年10月—2017年11月本院收治的70例晚期非小细胞肺癌患者作对象,按电脑数字表法随机分组,每组各35例,对照组施予常规化疗,实验组于此基础施予化瘀散结方治疗,对比分析两组患者CEA、CYFRA21-1、miR及MMP表达。结果治疗后,实验组CEA是(20.05±4.29)ng/m L,比对照组(26.29±5.27)ng/m L低,且实验组CYFRA21-1是(3.10±2.07)ng/m L,比对照组(4.27±2.10)ng/m L低,差异有统计学意义(P<0.05);实验组miR-21、miR-31及miR-155表达均比对照组低,差异有统计学意义(P<0.05);实验组MMP-2、MMP-9及MMP-11表达也比对照组低,差异有统计学意义(P<0.05)。结论化瘀散结方治疗晚期非小细胞肺癌有助于改善患者CEA、CYFRA211、miR及MMP表达,值得推广。
Objective To research the effect of Huayu Sanjie Formula on the patients with advanced non-samll cell lung cancer and its influence on the expressions of carcino-embryonic antigen(CEA),cytokeratin-19-fragment(CYFRA211),miR and matrix metalloproteinase(MMP).Methods Seventy cases of patients with advanced non-samll cell lung cancer who admitted to our hospital from October 2015 to November 2017 were randomly divided into control group and experimental group according to computer-generated number table method,with 35 cases in each group.The control group was treated with conventional chemotherapy,on the basis of the experimental group was treated with Huayu Sanjie Formula.The expressions of CEA,CYFRA211,miR and MMP were compared between the two groups.Results After treatment,the CEA in the experimental group was(20.05±4.29)ng/m L,which was lower than that of the control group[(26.29±5.27)ng/m L],and the CYFRA21-1 in the experimental group was(3.10±2.07)ng/m L,which was lower than that of the control group’s(4.27±2.10)ng/m L(P<0.05).In the experimental group,the expressions of miR-21,miR-31 and miR-155 were all lower than those of the control group with statistically significant(P<0.05).The expressions of MMP-2,MMP-9 and MMP-11 in the experimental group were also lower than those of the control group with statistically significant(P<0.05).Conclusion Huayu Sanjie Formula can help to improve the expressions of CEA,CYFRA211,miR and MMP of the patients with advanced non-samll cell lung cancer,which is worthy to be popularized.
作者
段铮
周庆伟
孙宏新
DUAN Zheng;ZHOU Qingwei;SUN Hongxin(The Second Affiliated Hospital of Henan University of Traditional Chinese Medicine,Zhengzhou 450000,Henan,China;The First Affiliated Hospital of Henan University of Traditional Chinese Medicine,Zhengzhou 450000,Henan,China)
出处
《辽宁中医杂志》
CAS
2020年第1期89-92,共4页
Liaoning Journal of Traditional Chinese Medicine
基金
2017年河南省中医药科学研究专项课题(2017ZY2063)
河南省省属高校科研专项(2014KYYWF-ZZCX3-07)
河南中医药大学第二附属医院项目(2015005).
关键词
化瘀散结方
晚期非小细胞肺癌
癌胚抗原
细胞角蛋白19片段
miR表达
基质金属蛋白酶
Huayu Sanjie Formula
advanced non-samll cell lung cancer
carcino-embryonic antigen
cytokeratin-19-fragment
miR expression
matrix metalloproteinase
作者简介
段铮(1984-),男,山西晋城人,主治医师,硕士研究生,研究方向:中医药防治恶性肿瘤。
